Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary

November 12, 2024

NASDAQ US Health Care Biotechnology earnings 43 min

Earnings Call Speaker Segments

Zack Kubow

executive
#1

Thanks, Operator, and good afternoon to all of you. We appreciate your participation in today's call covering Corvus Pharmaceuticals' business update and financial results for the third quarter of 2024. Here to discuss the results and business updates are Richard Miller, our Chief Executive Officer; Leiv Lea, Chief Financial Officer; Jeff Arcara, Chief Business Officer; Jim Rosenbaum, Senior Vice President of Research; and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences. The executive team will begin with some prepared remarks, after which we'll move to a question-and-answer session. I want to remind everyone that management's comments today, along with responses to questions, will contain forward-looking statements. Such statements rest on estimates and assumptions as of today and carry risks and uncertainties that could lead actual results to differ materially from those expressed or implied by those statements, including the risks and uncertainties described in Corvus' quarterly report on Form 10-Q for the quarter ended September 30, 2024, which was filed today, as well as other filings the company makes with the SEC from time to time. The company assumes no obligation to publicly update or revise any forward-looking statements, except as required by law; with that, I'd like to hand the call over to Leiv Lea. Leiv?

Leiv Lea

executive
#2

Thanks, Zack. I'll start by giving a brief look at how we did financially in the third quarter of 2024, and after that I'll hand things over to Richard for an update on the business. R&D expenses for the third quarter of 2024 came to $5.2 million, versus $4 million during the same period in 2023. That $1.2 million rise was mainly driven by higher costs for the soquelitinib clinical trial. Our net loss in the third quarter of 2024 was $40.2 million, which included a noncash loss of $0.7 million tied to Angel Pharmaceuticals, our partner in China. On top of that, we booked a noncash loss of $32.8 million stemming from the change in fair value of Corvus' warrant liability during the third quarter of 2024. That compares with a net loss of $6 million in the same period in 2023, which included a $0.9 million noncash loss from Angel Pharmaceuticals. Total stock compensation expense in the third quarter of 2024 was $0.7 million, compared with $0.5 million in the same period in 2023. As of September 30, 2024, Corvus held cash, cash equivalents and marketable securities amounting to $41.7 million, versus $27.1 million at December 31, 2023. Notably, in connection with our financing in May 2024, we also sold common stock warrants carrying an exercise price of $3.50 per share that expire on June 30, 2025. One investor exercised their warrants early in October, which brought $5.9 million in cash to the company. Should all the remaining warrants be exercised, we would receive roughly $54 million in additional cash. Given our current plans, we expect our cash, including the recent early exercise of common stock warrants, to provide runway into 2026. I'll now hand the call over to Richard, who will go over our clinical progress and provide more detail on our strategy and plans.

Richard Miller

executive
#3

Thanks, Leiv, and hello to all of you this afternoon. We appreciate your joining the call today for this update on our business. On several fronts, we're pushing forward with our lead programs involving soquelitinib. Enrollment is now open for a registration Phase III study in peripheral T-cell lymphoma, or PTCL, and a Phase I study in atopic dermatitis is progressing as intended. Soquelitinib is an oral, first-in-class agent that selectively inhibits ITK in order to modulate and control parallel signaling pathways within the immune system. Evidence keeps accumulating — from our own clinical work as well as preclinical research done by us and by others — that this mechanism of action could deliver a potent new way to treat a wide variety of immune diseases and cancers. The speed and efficiency with which we moved into autoimmune conditions like atopic dermatitis were made possible by our T-cell lymphoma trials, which gave us valuable insight into dosing, safety, pharmacokinetics and, most importantly, effects on immune cells; now I'll go into greater detail about our progress, beginning with the Phase I clinical trial of soquelitinib in atopic dermatitis patients. The trial is set up to enroll 64 patients who have moderate to severe atopic dermatitis and whose disease has progressed on at least 1 prior topical or systemic therapy. This is a randomized, placebo-controlled study, and patients along with their treating physicians are blinded to which treatment is assigned. The company itself is not blinded, so we're able to assess the data as the trial moves forward. Four dosing cohorts are enrolled in sequence: 100 milligrams twice per day, 200 milligrams once per day, 200 milligrams twice per day and 400 milligrams once per day. The reasoning behind these dosing regimens comes from pharmacokinetic and pharmacodynamic data generated in our lymphoma trial. Within each cohort, patients are randomized at a 3:1 ratio to get either the active drug or placebo, for a total of 16 patients per cohort — 12 active, 4 placebo. Treatment lasts 28 days, followed by another 30 days off therapy, for a total of 58 days of trial participation and endpoint monitoring. We've finished enrollment, including all follow-up, in the initial 16-patient cohort, and the Data Safety and Monitoring Review Committee has wrapped up its review with no safety signals seen. The second cohort is enrolling now under the same design as the first, except the soquelitinib dose is 200 milligrams once daily — the same total daily dose as the first cohort, which was 100 milligrams twice daily. Cohorts 3 and 4 will look at higher daily doses using the same design: 200 milligrams twice daily and 400 milligrams once daily, respectively. For reference, the dose used in our Phase III lymphoma trial is 200 milligrams twice daily, which delivers continuous full receptor occupancy. The primary endpoint is safety and tolerability, and efficacy is assessed through the clinically validated measurements of improvement in Eczema Area and Severity Index, also known as EASI score, and the Investigator Global Assessment, or IGA score. We're also looking at serum levels of Th2 and Th17 cytokines — IL-4, -5, -13, -17, and quite a few others; our thinking is that through these serum measurements, we might be able to figure out what's happening with cellular cytokines. And it's possible that this could help steer how we monitor patients or assess disease going forward. There's another characteristic of selective ITK inhibition worth mentioning. Work that was published by researchers at Cornell University last summer, in 2024, along with work from Janssen Research back in 2019, demonstrated that the ITK protein governs a kind of toggle between inflammatory Th17 cells and anti-inflammatory T regulatory, or suppressor, cells. While the ITK protein remains active, Th17 differentiation is what predominates. When ITK is inhibited, the result is a move toward Tregs and away from Th17. For their experiments, the Cornell team made use of soquelitinib. The group at Janssen relied on siRNA to knock down expression of the ITK protein, since no selective ITK inhibitor existed at that point; those studies, along with others, point to the idea that because Tregs get induced, soquelitinib's anti-inflammatory activity might last a very long time. There's a lot of desire for an oral drug with a good safety profile for atopic dermatitis, and investigators and collaborators have been giving us encouraging feedback about the profile we anticipate for soquelitinib. All in all, we're extremely enthusiastic about how the atopic dermatitis trial is going; this December, we intend to share the full safety and efficacy data set from Cohort 1 plus whatever data are available from Cohort 2; our plan is to set our results against similar published results from approved therapies that are in use today for atopic dermatitis. To sum up, we think soquelitinib offers a number of possible benefits when it comes to treating immune diseases — it's taken by mouth, has an appealing safety and tolerability profile, works through a novel mechanism, produces lasting responses, and can potentially cover a wide range of autoimmune and allergic conditions, including comorbidities like asthma among atopic dermatitis patients. Support for the broad promise of soquelitinib and our next-generation ITK inhibitors comes from fresh preclinical data demonstrating activity of soquelitinib in systemic sclerosis, a chronic autoimmune condition that leads to fibrosis and inflammation across numerous organs, the skin among them; those findings are going to be presented at the end of this week during the Annual Meeting of the American College of Rheumatology. We keep moving forward with an array of second- and third-generation ITK inhibitor product candidates, engineered to provide precise T-cell modulation tuned for particular immunology indications. Our preclinical development efforts are concentrated on asthma, psoriasis, scleroderma, inflammatory bowel disease, and fibrotic diseases, with many additional indications singled out for later work; now let me give you an update on soquelitinib in oncology. This past September, we launched our registrational Phase III clinical trial in relapsed PTCL. Right now there are no agents that carry full FDA approval for treating relapsed PTCL, and for soquelitinib in relapsed T-cell lymphoma, the FDA has awarded both orphan drug designation and Fast Track designation. The trial is set up to randomize 150 patients between soquelitinib and standard-of-care chemotherapy, which means either pralatrexate or belinostat. Progression-free survival serves as the study's primary endpoint. Patient enrollment is currently underway at several clinical sites, and we remain on schedule with our plan. Our team is working to bring additional sites online, aiming for roughly 40 to 50 centers across the United States, Australia, Canada and South Korea to take part in the trial. The United States will account for the vast majority, with sites including MD Anderson, Memorial Sloan Kettering, City of Hope, Washington University and other prominent institutions. We are very pleased to have these leading centers involved, given their deep experience and expertise running clinical trials in T-cell lymphomas. We have stopped enrolling new patients in our Phase I trial, but we are still monitoring patients on therapy as they finish their scheduled follow-up assessments. 4 patients remain on therapy, among them 3 with the previously reported complete responses, which are sustained, and 1 patient who achieved a partial response. That partial response patient continues to show tumor regression over time but has not yet reached a complete response. For 1 additional patient who achieved a complete response, treatment was stopped while in CR after 24 months on therapy, per the study protocol.

Richard Miller

executive
#4

In the Phase III population, the objective response rate is still 39%, which works out to 9 of 23 patients. That breaks down into 6 complete responses plus 3 partial responses. Median PFS is unchanged at 6.2 months. For belinostat, the published median PFS is 1.6 months, and for pralatrexate it is 3.5 months. We're additionally working toward a single-agent soquelitinib trial in solid tumors, specifically in relapsed renal cell cancer, or RCC, which would represent a novel immunotherapy strategy for this condition. The biochemical mechanism of action along with preclinical solid tumor findings for soquelitinib tumor immunotherapy are currently in press at the peer-reviewed journal Drug Discovery, a Nature Partner Journal. Because we're prioritizing our atopic dermatitis and PTCL studies, we now intend to launch our solid tumor clinical study at some point in early 2025. We're likewise continuing to move forward our other clinical-stage development efforts. With ciforadenant, we've been among the leaders in developing adenosine 2A receptor antagonism as a cancer treatment; this encompasses our Phase Ib/II study being run together with the Kidney Cancer Research Consortium. That study is assessing cifo as a possible first-line treatment for metastatic renal cell cancer combined with ipilimumab and nivolumab. Enrollment is taking place at MD Anderson, Vanderbilt, Duke and the University of Pennsylvania. According to the latest data analysis, dated September 30, 46 patients had enrolled, and the study keeps meeting our prespecified statistical hurdle for continuation — namely, reaching at least a 50% improvement in the deep response rate of 32% seen with the ipi and nivo combination by itself. Deep response rate means the CR rate plus the PR rate, counting only PRs that reached more than 50% tumor volume reduction. Together with our partners at the Kidney Cancer Research Consortium, we've chosen to keep following patients in the study before we present the data. So we won't present these data at the GU Malignancy Conference happening in late November, and instead we'll aim for a presentation at some point in early 2025. Beyond RCC, new findings showing ciforadenant's potential against prostate cancer were presented this past weekend during an oral session at the Society for Immunotherapy of Cancer, or SITC, Annual Meeting, where it was chosen as one of the top 100 abstracts. Dr. Larry Fong of the Fred Hutch Cancer Center and UCSF led this research. The results show cifo's potential to get past immunotherapy resistance in metastatic castration-resistant prostate cancer. This involves clarifying how the adenosine pathway affects the immunobiology of the disease, such as the significance of immunosuppressive myeloid cells and the adenosine gene signature, a biomarker that Corvus and academic collaborators discovered and published. These preclinical findings extend the results from an earlier completed Phase Ib/II clinical study of cifo in metastatic castration-resistant prostate cancer patients, where PSA partial responses were seen among those given cifo by itself and in combination with atezolizumab. All told, these findings, in our view, demonstrate that ciforadenant may represent a meaningful step forward for individuals whose tumors do not respond to checkpoint inhibitors, and they lend support to the clinical study we are currently running that combines it with ipi and nivo in first-line renal cell cancer. These results likewise emphasize how valuable the adenosine gene signature is as a biomarker going forward. Turning to what remains of 2024 and looking ahead to 2025, we have significant clinical milestones lined up for soquelitinib. Here is what is coming: first, a presentation of preclinical findings at the American College of Rheumatology conference later this week; second, initial results from Cohort 1 and Cohort 2 of our Phase I atopic dermatitis study in December; third, final results across all 4 cohorts of that Phase I atopic dermatitis study during the first half of 2025; fourth, launching a Phase II study of soquelitinib in solid tumors in early 2025, with initial results expected in late 2025; and fifth, keeping up our work to activate sites and build enrollment for the registration Phase III study of soquelitinib in PTCL. With the cash we hold today plus proceeds from exercised outstanding warrants, our runway extends into 2026, which lets us deliver on these key milestones and further show the worth of our programs — especially the considerable potential of ITK inhibition in immunology and cancer. We are eager to share updates on our programs over the next several quarters. At this point I will hand the call to the Operator for the Q&A session. Operator?

Li Watsek

analyst
#5

Rich, could you share your thoughts on how quickly ITK inhibition affects the clinical scores in AD? Also, would you anticipate the EASI score continuing to get better once we pass day 28? And could you give us some sense of how you view the threshold for success, considering this is an oral medication?

Richard Miller

executive
#6

Sure. Thanks for asking, Li. The response happens quite fast. Within roughly the initial 7 days, we're already seeing improvement. I'll go into greater detail on this during our December call; our expectation is that the bar for success will resemble what has been seen with other approved therapies, such as DUPIXENT; we'll examine the 28-day data and set it against 28-day data from comparable compounds or from DUPIXENT and other approved therapies. Given soquelitinib's mechanism of action and its potential to deliver even more improvement, we anticipate a highly durable effect.

Roger Song

analyst
#7

Thanks. Nice work on the advances; now — I have a few questions that also tie to the atopic dermatitis and that data announcement. Since you're going to have the first readout of data in December, followed by the final data in early 2025, what should our expectations be regarding the follow-up duration for those cohorts? Also, when it comes to the efficacy endpoint, do you expect those endpoints to show differing kinetics depending on how long the follow-up is?

Richard Miller

executive
#8

In December, we'll present the 28-day data. We'll describe the kinetics of — like I said in response to the previous question, responses are appearing quickly, roughly inside a week. The 28-day data will be reported. Naturally, I'd anticipate that we'll have full follow-up for Cohort #1. For Cohort # 2, we won't have all of the 58-day follow-up. Once we move into Cohort 3 and 4, we'll begin assessing how the responses behave in terms of kinetics and durability across the 2-month period.

Roger Song

analyst
#9

Understood. As a follow-up regarding the dose, drawing on the PK/PD along with preclinical modeling, are you anticipating dose dependence across the 4 arms being evaluated in Phase I?

Richard Miller

executive
#10

The study's aim was to identify the optimal dose, and we examined 4 distinct doses, dosing regimens and doses. My expectation would be that efficacy gets better with higher dosing, simply from what lymphoma trials have shown us and from achieving greater target saturation; nonetheless, atopic dermatitis is not the same disease as lymphoma. Therefore I can't be certain that, that will actually be the outcome. Yet our trial was designed to establish what the optimal dose would be. The lymphoma studies gave us a benefit here, since they handed us a kind of floor and ceiling to look into. So, Roger, maybe you could add a little more on that. That 100-milligram dose, the first cohort — we know from our lymphoma work — gets you decent saturation of the target, though not full saturation, just decent. And we can — from our lymphoma patients we have measurements that let us capture this right after a dose is taken and then at the nadir, the lowest point; and what we know is that with 100 milligrams you get decent coverage, but it isn't complete. At elevated dosing—say 200—we're aware that you achieve improved coverage and so forth. So the real issue becomes: for atopic dermatitis, which isn't lymphoma, what level of coverage is actually required? Is it truly necessary to have complete occupancy at all times? That's something nobody currently has an answer to, and we intend to determine it.

Aydin Huseynov

analyst
#11

Richard, nice work on the quarter's advances. Two things from me. To start, back to atopic dermatitis — you've got 64 patients in the study. What prior treatment is most common among them? Something topical, such as ruxolitinib? Or a systemic option like dupilumab? Also, any comments from physicians about how eager patients are, and so on — any specifics you can offer?

Richard Miller

executive
#12

All right. First off, Aydin, not all 64 are enrolled at this point. The goal is 64 enrolled. Cohort #2 is being enrolled right now. To qualify, a patient must have not responded to a systemic or topical AD therapy, while still having moderate or severe disease. Thus far, those we've enrolled — and we'll give more specifics in December — haven't had a systemic therapy fail, though topical treatments have failed for them. Nearly every patient treated to date stopped their topical treatment during the time they're taking our drug.

Aydin Huseynov

analyst
#13

All right, got it. So for the most part, what we're seeing is a kind of topical failure rather than — essentially, it's the patient population from before DUPIXENT.

Richard Miller

executive
#14

Up to this point; up to this point. Right now, we're midway through the study.

Aydin Huseynov

analyst
#15

All right, that clears things up. And yeah, I'd like to circle back to the PTCL indication as well — this may be a bit of an old question — but is there anything new regarding the Phase Ib patients? Have any CRs converted to PRs, or have any PRs — has any PR turned into a CR, or is there any news about the duration of response from Phase Ib?

Richard Miller

executive
#16

Well, as I said during my remarks, 4 patients remain on therapy. Of that group, 3 are CRs — oh Lord, I can't recall exactly, somewhere in the range of 6 to 12 months out at minimum. For one of the PRs, the tumor has kept shrinking; that individual has now been receiving treatment for roughly 18 months, and there's just gradual progress, ongoing gradual improvement in the disease. That hasn't reached CR status yet, though it does look quite encouraging in that respect. Now, regarding one of those CRs, we halted treatment while the patient was in CR — the protocol doesn't allow us to go past 24 months of therapy. So that individual came off treatment while still in CR.

Aydin Huseynov

analyst
#17

All right. So a single PR could possibly become a CR. And what accounts for CRs being so widely available compared with PRs? We're seeing more CRs and PRs, which isn't typical. So what's your explanation — what does that reveal regarding the mechanism of action in this case?

Richard Miller

executive
#18

Well, I believe it reveals that this works well for wiping out microscopic disease, and it works well for wiping out — keep in mind, these tumors differ greatly from one another; they carry many distinct mutations and many distinct clones, and so on. And I believe what that reveals is that the mechanism of action can address a wide range of tumors along with the mutations tied to them. By contrast, if you give someone, say, a chemotherapy agent, eventually you'll wind up selecting resistant clones; we appear to be less prone to resistance developing. And I believe that happens because an immune response is what we're bringing about. And an immune response, as you're aware, is capable of reacting to various antigens and to a range of antigen diversity. Does that make sense?

Aydin Huseynov

analyst
#19

Yeah, definitely. Definitely. And my final question concerns systemic sclerosis — the preclinical results that they're going to present. So that's yet another difficult-to-treat condition, an autoimmune one. Historically, Dave was seeking 2 endpoints for systemic sclerosis. One of them is lung FVC, while the other is the Rodnan skin score. So where do you figure soquelitinib might place its emphasis? I realize it's very early for this, but this drug is active, with one oncology indication and one autoimmune indication. So it wouldn't be entirely surprising if at some point you went straight into Phase II. So I just wanted to hear your thinking regarding systemic sclerosis.

Richard Miller

executive
#20

Yeah. What I mean is, the lung disease is what kills patients — interstitial pneumonitis along with fibrotic lung disease, meaning interstitial lung disease. So that's the aspect to concentrate on. And concentrate on it is exactly what we've done. So the model that will be — and the abstract is already available on this, I believe the paper comes Sunday at AACR — is a highly interesting model, a really good one, arguably the finest animal model for systemic sclerosis. These animals develop — what they carry is a FRAT2 mutation. It's very much a Th2 disorder. And they develop fibrosis, fibrotic lung disease, they develop right heart failure, and treatment with soquelitinib causes all of that to respond. Beyond that, we've tested soquelitinib as well in the standard bleomycin fibrotic interstitial lung disease, and in that model too it's quite active. So I believe eventually, for systemic sclerosis, what I mean is, lung disease would be our focus since that's the thing that kills patients. And that's the largest — the most severe element of the problem. And as you're aware, lung disease and right heart disease travel together in arterial hypertension and so on. So that would be — that's a disease that interests us; it additionally provides a window into fibrotic diseases. Fibrosis is very much Th2. We block Th2 quite effectively. And so, this unlocks an entirely new set of diseases tied to fibrosis, ranging from scleroderma to cirrhosis, to other fibrotic diseases.

Aydin Huseynov

analyst
#21

Got it. Yeah, that tracks; and apologies, one final thing I'd like to raise — in what way would dosing differ when it comes to oncology versus autoimmune diseases? Those represent two major sorts of indications. I just wanted to get your perspective on that.

Richard Miller

executive
#22

Well, my sense is that speculating at this point is a bit premature. What I mean is, there's a trial underway right now, and from it we'll gain considerable insight regarding dosing and regimen. Still, I suppose I'll take a risk here and state that my belief is atopic dermatitis won't require continuous treatment. Cancer, in my view, will.

Graig Suvannavejh

analyst
#23

Congrats on the momentum you've built. Let me go back to the readout — the atopic dermatitis interim data expected in December — regarding EASI. Could you make clear whether you'll report specifically on EASI-50 as well as EASI-75? Then a follow-up: going back to what you said, Richard, answering, I believe, one of the earliest Q&A questions, about where the bar for success sits. You mentioned expecting something comparable to approved agents like dupi. But I wonder — given that yours is an oral therapy — whether you think you must match the efficacy of injectables such as dupi? Then I have one more follow-up.

Richard Miller

executive
#24

All right, thank you for asking. We anticipate reporting for Cohort 1 and Cohort 2. Of course, Cohort 1 will have more follow-up, since it was enrolled first. Our plan is to report the mean percent EASI score reduction for placebo and for active. We intend to report EASI-50, EASI-75, EASI-90. We intend to report IGA 0 and 1; these are very standard measures. So that's what we'll be reporting. Clearly, safety will be reported too. Now, your question about "what will we compare it to?" Well — our regimen, again, this is the first dose we've tested; it's 28-day dosing. We can compare, and we will compare, to, say, the DUPIXENT Phase I trial, where their dose was already optimized and treatment ran for 4 weeks and 12 weeks. So comparisons to things like that are possible. That's what we plan to do. Now, your question about whether we must be as good because we're oral and safe and more convenient — we're pretty excited about our drug's mechanism of action. So I want to be better, I plan to be better.

Graig Suvannavejh

analyst
#25

All right, I’m grateful for that, and I’m grateful for how sure you are about what that readout could show. Then, as a follow-up that sort of flows from talking about an oral agent: would you mind reminding me — since there’s clearly appeal in an atopic dermatitis treatment taken by mouth rather than given as an injection — how the competition shapes up when it comes to oral medicines sitting in the clinic, and roughly where do we stand on clinical development timing compared with, say, certain other oral programs with a bigger profile that you watch closely?

Richard Miller

executive
#26

Honestly, that question is quite difficult. As you’re aware, a large number of drugs are being developed for atopic dermatitis. The majority of them are injectable biologics. A few oral compounds are in the clinic. Whether I’m able to say anything about them, I’m not certain. My impression is that they are fairly early. What their data looks like, I don’t truly know. I’m also aware that some data readouts are coming before this year ends, so I doubt I can say anything about how our product compares with them.

Jeff Jones

analyst
#27

I suppose I'll move away from AD and return to PTCL; regarding the Phase III study and its primary endpoint of PFS, what's your approach in the trial for those patients who are complete responders and subsequently undergo transplant? And then I'd like your perspective on what constitutes the bar for success here, considering some of the data on the PI3K inhibitors that we're seeing at ASH right now? And then I have a follow-up.

Richard Miller

executive
#28

All right. So to begin with, Jeff, this is a randomized trial, and the standard of care, belinostat and pralatrexate and the soquelitinib arms each have an equal number of patients; therefore, should you proceed to a bone marrow transplant, you are censored at that moment. We keep following you, but you are censored at that moment. The quantity of patients that's expected to undergo transplant in a study such as this, perhaps 10%, perhaps not even that high. So that won't be a major factor. But the response to your question is, they would be censored. You tally their response and their PFS up to the point in time that they go on for a transplant. Now, the second part of your question was criteria for success, I believe.

Jeff Jones

analyst
#29

That's right.

Richard Miller

executive
#30

Yeah, so, okay, the protocol already accounts for that, and the same goes for censoring — everything is specified in the protocol and FDA has reviewed all of it. So the statistical plan actually provides roughly 90% power. I believe it's 89% power for detecting a 1.5-month gain versus the control arm, which works out to a hazard ratio of approximately 0.56. So that's the bar we have to clear. Now, coming back to the transplant issue, just so everyone's clear — I mean, the majority of patients are too elderly for a transplant. This illness is largely one affecting older individuals. Most patients are too old, plus you need to achieve a good remission before a transplant is even possible. That's the reason only such a small subset of patients actually receives a transplant. And it's also why interpreting transplant data is so difficult, since you're already selecting a highly favorable patient population from the start. But regardless, in our trial, we handle this through censoring those data. Does that make sense?

Jeff Jones

analyst
#31

Thanks for that. Yeah, it does. And I suppose — so, I mean, the information that's currently available at ASH regarding PI3 kinase inhibitors, that's really — at this stage it's ORR data. But I suppose, just what your perspective is on what you're observing there with a few of those, I suppose, somewhere in the range of 40% to 60% ORRs across a couple of those studies.

Richard Miller

executive
#32

Yeah. So PI3Ks have existed for quite a while in PTCL. They provide you with decent responses. Typically those responses don't last long at all. Those drugs come with high toxicity, including liver abnormalities and blood-related abnormalities too. I don't truly believe that represents a meaningful competitor for soquelitinib, if our trial turns out positive; and there's another point worth mentioning there. Really, the soquelitinib trial is positioning one for the subsequent trial, which would be frontline. I mean, this is a registration approvable trial. But the following study, which people already are eager to conduct, is to pair soquelitinib with chemotherapy in the frontline setting and maybe employ it as maintenance therapy given its safety and convenience. That's not something you'd do with a PI3K. You can't simply throw that together with a variety of chemotherapy drugs. From a safety perspective, that would be too hard to accomplish. And employing it as maintenance would likewise be problematic.

Jeff Jones

analyst
#33

Understood. Alright, thanks for that. A brief additional question regarding the renal cell trial involving soquelitinib. When it comes to picking which patients to enroll, will you be revisiting absolute lymphocyte counts, or relying on the number of prior therapy lines? What's your approach to assessing T-cell health in that setting?

Richard Miller

executive
#34

Right. Well, that isn't something we're applying as an inclusion requirement, even though we do plan to gather those data. Renal patients haven't been hit as hard on the immunological front compared with the lymphoma population; so my sense is we'll fare better in that regard, since lymphoma patients tend to be fairly immunosuppressed both from the illness itself and from the kinds of treatments they've received. That issue is diminished in renal.

Jeff Jones

analyst
#35

All right. So basically you're gathering the information and then just seeing how things shake out for those endpoints or biomarkers afterward?

Richard Miller

executive
#36

Correct. Okay, that's everything we've got in terms of questions today. Thanks to all of you for joining in, and we're eager to share an update with everybody in December regarding our atopic dermatitis trial. Thanks so much.

Operator

operator
#37

And this concludes today's call. Thank you for participating. You may all disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.